Press release
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034, Finds DelveInsight | TuHURA Biosciences, Philogen, Merus, Immunomic Therapeutics, Phio Pharmaceuticals, Kymera Therapeutics
Merkel Cell Carcinoma Market Insights
DelveInsight's latest report, "Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast," combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034
Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France.
Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM.
According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor.
Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA).
The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells.
DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others.
Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape.
MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, "As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively." This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth.
Scope of the Merkel Cell Carcinoma Market Report:
Study Period: 2020-2034
Coverage: 7MM [US, UK, EU4 (France, Germany, Italy, and Spain), and Japan]
Key Merkel Cell Carcinoma Companies
Key Merkel Cell Carcinoma Therapies
Merkel Cell Carcinoma Therapeutic Assessment
Merkel Cell Carcinoma Market Dynamics
Competitive Intelligence Analysis
Merkel Cell Carcinoma Unmet Needs, KOL Views, Analyst Views, Merkel Cell Carcinoma Market Access and Reimbursement.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Merkel Cell Carcinoma Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Merkel Cell Carcinoma Background and Overview
8. Merkel Cell Carcinoma Treatment
9. Merkel Cell Carcinoma Epidemiology and Patient Population in the 7MM
10. Merkel Cell Carcinoma Patient Journey
11. Merkel Cell Carcinoma Marketed Drug
12. Merkel Cell Carcinoma Emerging Drugs
13. Merkel Cell Carcinoma: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034, Finds DelveInsight | TuHURA Biosciences, Philogen, Merus, Immunomic Therapeutics, Phio Pharmaceuticals, Kymera Therapeutics here
News-ID: 4258460 • Views: …
More Releases from DelveInsight Business
Pompe Disease Market Set for Robust Growth Through 2034, Driven by Breakthrough …
The Pompe disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Sanofi, Genzyme, Amicus Therapeutics, GeneCradle Therapeutics, Astellas Gene Therapies, Spark Therapeutics, Aro Biotherapeutics, Maze Therapeutics, Valerion Therapeutics, Actus Therapeutics, Roche, and Lacerta Therapeutics, among others.
DelveInsight's "Pompe Disease Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the Pompe disease treatment market,…
Gallbladder Cancer Clinical Trials Analysis 2025 Innovative Combinations and Imm …
DelveInsight's "Gallbladder Cancer - Clinical Trials Analysis, 2025" explores a rapidly advancing pipeline targeting one of the most aggressive biliary tract malignancies. With limited curative options and late-stage diagnosis in most patients, ongoing studies are focusing on immunotherapy, targeted therapies, and novel drug combinations to improve survival outcomes.
Checkpoint inhibitors, including PD-1 and PD-L1 antibodies, are being investigated alone and in combination with chemotherapy to extend overall survival in advanced cases.…
Familial Chylomicronemia Syndrome Market and Epidemiology 2034: Treatment Market …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome…
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market to Grow Positively …
(New York, Nevada, Las Vegas), DelveInsight's "Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Recurrent Head and Neck Cancer Squamous Cell Carcinoma market share of the individual therapies, current and forecasted Recurrent Head and Neck Cancer Squamous Cell Carcinoma market size from 2019 to 2032 segmented by seven major markets. The report also offers…
More Releases for Merkel
Rising Incidence Of Skin Cancer Fuels Growth In Merkel Cell Carcinoma Treatment …
Which drivers are expected to have the greatest impact on the over the merkel cell carcinoma treatment market's growth?
The escalating occurrence rate of skin cancer cases is likely to stimulate the merkel cell carcinoma treatment market's expansion. Skin cancer refers to a specific variety of cancer that originates in the skin cells. It transpires when skin's normal cells experience genetic mutations that make them proliferate uncontrollably, leading to the creation…
Merkel Cell Carcinoma Treatment Market 2024 Research Report
Merkel Cell Carcinoma Treatment Market
Merkel cell carcinoma treatment includes medical interventions and therapies used to manage Merkel cell carcinoma, a rare and aggressive skin cancer.
The global Merkel Cell Carcinoma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The market for Merkel cell carcinoma treatment is driven by the increasing incidence of…
Metastatic Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Metastatic Merkel Cell Carcinoma pipeline constitutes 13+ key companies continuously working towards developing 15+ Metastatic Merkel Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Metastatic Merkel Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Merkel…
Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Advanced Merkel cell carcinoma Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Merkel Cell…
Global Merkel Cell Carcinoma Treatment Market Insights, Forecast
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. The global Merkel Cell Carcinoma Treatment market is…
Merkel Cell Carcinoma - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Merkel Cell Carcinoma - Pipeline Review, H1 2017" to its huge collection of research reports.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts…
